New approach for cancer prevention in BRCA1 mutation-positive women

New approach for cancer prevention in BRCA1 mutation-positive women from Josef Penninger
The figure shows mammary glands from 4-month-old mice carrying a mutation in the BRCA1 gene. Blocking the RANKL/RANK system leads to largely normal mammary glands (right) whereas malignant changes and carcinomas could be found in the control group (left). Credit: (c) IMBA

Women with inherited mutations in the BRCA1 or BRCA2 genes are at substantially higher risk of breast cancer. For these women, effective prevention strategies are their best hope to reduce their breast cancer risk. In FY11, Dr. Josef Penninger received an Innovator Award from the BCRP to pursue a project that could immediately impact breast cancer prevention.

Dr. Penninger's team was the first to demonstrate that two proteins, RANK and RANKL, are important regulators of bone loss, ultimately leading to FDA approval of RANKL-blocking drugs for osteoporosis. His team later discovered that the RANK/RANKL system is also essential for the formation of the lactating mammary gland during pregnancy and that it forms a crucial molecular link between sex hormones, development of , and subsequent metastasis to bone. Interestingly, RANK signaling was found to act on mammary epithelial progenitor cells, which are also believed to be "seed cells" for in carriers with BRCA1/2 mutations. With his BCRP Innovator Award, Dr. Penninger investigated whether RANKL inhibition could be used to prevent breast cancer in mouse models.

Dr. Penninger's results showed that inactivation of RANK markedly delayed and in some cases even prevented the development of breast cancer in mice with mutated BRCA1. The loss of RANK also impaired the progression of to high-grade malignancies. These effects were observed both when RANK was inactivated genetically and when mice received preventive pharmacological RANKL inhibitors.

Dr. Penninger has documented that RANK/RANKL are highly expressed in pre-malignant lesions and breast cancer in women with BRCA mutations, and that common variants of RANK are associated with increased among these women. Future experiments, especially carefully designed clinical trials, will be needed to assess whether RANKL inhibitors offer an advantage over current prevention techniques like Tamoxifen or oophorectomy. However, these findings raise the exciting possibility that inhibition of RANKL, for which there is already a drug that has a good safety record and is approved by the Food and Drug Administration, could offer a novel, targeted approach for breast cancer prevention in women with BRCA1 mutations.

Explore further

Therapeutic inhibition of RANK pathway reduces breast cancer recurrence

More information: Verena Sigl et al. RANKL/RANK control Brca1 mutation-driven mammary tumors, Cell Research (2016). DOI: 10.1038/cr.2016.69
Journal information: Cell Research

Provided by US Department of Defense Congressionally Directed Medical Research Programs
Citation: New approach for cancer prevention in BRCA1 mutation-positive women (2016, December 15) retrieved 25 June 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors